BioPorto cuts 2026 revenue outlook to DKK 38-48 million after divestment

  • BioPorto cut FY 2026 total revenue guidance to DKK 38 million–48 million from DKK 48 million–58 million following divestment of its antibody business, effective April 8, 2026.
  • Total NGAL revenue outlook was maintained at DKK 33 million–42 million.
  • Updated FY 2026 adjusted EBITDA loss forecast widened to DKK 58 million–68 million from DKK 50 million–60 million.
  • BioPorto lowered its 2028 total revenue target to DKK 135 million–185 million from DKK 150 million–200 million.
  • Cash flow positive expectation shifted to first half 2028 from second half 2027, while adjusted EBITDA margin target stayed at at least 15%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioPorto A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604080916OMX_____CNEWS_EN_GNW1001174717_en) on April 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.